Generic filters

Johnson & Johnson Announces Submission to World Health Organization for Emergency Use Listing of investigational single-shot Janssen COVID-19 vaccine candidate

Johnson & Johnson (NYSE: JNJ) (the Company) announced that Janssen-Cilag International N.V. has submitted for Emergency Use Listing (EUL) to the World Health Organization (WHO) for the investigational single-dose Janssen COVID-19 vaccine candidate. The data package delivered includes interim efficacy and safety results from the Phase 3 ENSEMBLE clinical trial.


GSK and Vir Biotechnology expand coronavirus collaboration to advance new therapeutics for influenza and other respiratory viruses

GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Nasdaq: VIR) have signed a binding agreement to expand their existing collaboration to include the research and development of new therapies for influenza and other respiratory viruses. The expanded collaboration, which builds on the agreement signed in 2020 to research and develop therapies for coronaviruses,


Antiviral used to treat cat coronavirus also works against SARS-CoV-2

Researchers at the University of Alberta are preparing to launch clinical trials of a drug used to cure a deadly disease caused by a coronavirus in cats that they expect will also be effective as a treatment for humans against COVID-19. “In just two months, our results have shown that the drug is effective at inhibiting viral replication in cells with SARS-CoV-2,” said Joanne Lemieux, a professor of biochemistry in the Faculty of Medicine & Dentistry.


Search for COVID-19 drugs boosted by SARS discovery

An extensive search and testing of current drugs and drug-like compounds has revealed compounds previously developed to fight SARS might also work against COVID-19. Using the National Drug Discovery Centre, researchers from the Walter and Eliza Hall Institute identified drug-like compounds that could block a key coronavirus protein called PLpro. This protein, found in all coronaviruses, is essential for the virus to hijack and multiply within human cells, and disable their anti-viral defences.


73,000 Scientists collaborate over new COVID-19 Data Portal to speed up vaccine development

More than 73,000 users collaborate on new online platform set up by the European Open Science Cloud Initiative, where scientists share COVID-19 data and accelerate our understanding of the virus to help develop treatments and vaccines quicker. A new website that allows scientists to share difficult-to-find SARS-CoV-2 data from clinical trials, research centres, hospitals and national healthcare systems, has seen thousands of users collaborating to help beat the novel coronavirus.

Phase I clinical trial initiated for monoclonal antibody combination for the prevention and treatment of COVID-19

The first participants have been dosed in a Phase I trial of AZD7442, a combination of two monoclonal antibodies (mAbs) in development for the prevention and treatment of COVID-19. The trial, called NCT04507256, will evaluate the safety, tolerability and pharmacokinetics of AZD7442.(1) The trial will include up to 48 healthy participants in the UK aged 18 to 55 years and is funded by the

ROQUETTE Expands Excipient/API Services

ROQUETTE has opened a new pharmaceutical Application Development Center at its site at Lestrem, France, expanding its services for excipients and active ingredients to the pharmaceutical industry.

The 800 m2 lab offers compression, film coating or granulation, as well as the development of new galenic forms, one of the company’s latest innovations. ROQUETTE has developed an excipient for orodispersible tablets, a new form that melts directly in the mouth without the need for water, providing immediate action for the patient. The company will also provide expertise for pharmaceutical formulation.

Back to Top
Product has been added to your cart